Thrombus imaging agents

Figure 7.15 The P280 thrombus imaging agent peptide for labeling with technetium-99m. Possible Tc ligand atoms shown in hold type. (Adapted with permission from Figure 23 of Liu, S. Edwards, D. S. Chem. R(.v., 1999, 99(9), 2235-2268. Copyright 1999, American Chemical Society.)...

Technetium-labeled peptides and proteins have been investigated as potential thrombus-imaging agents. Complex 70, which combines 99mTc with the tripeptide motif Arg-Gly-Asp, binds GP Iib/IIIa recep-... 

Dougan H, Weitz JI, Stafford AR, Gillespie KD, Klement P, Hobbs JB, Lyster DM, Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents, Nucl. Med. Biol., 30 61-72, 2003. 

The suitability of aptamers as in vivo imaging agents is demonstrated in references [39-41], who used anti-neutrophil elastase and anti-thrombin aptamers for imaging of inflammation and thrombus in vivo, respectively. 

Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, Bulte JW, Robertson JD, Gaffney PJ, Wickline SA, Lanza GM. Improved molecular imaging contrast agent for detection of human thrombus. Magn. Reson. Med. 2003 50 411-416. 

Fig. 36.6a-C. DECT in status post-endovascular repair of AAA. a On the 80 kVp image, a type 2 endoleak (arrow) is identified in a 72-year-old male. The density of the contrast agent in the aneurysm sac is 320 HU. Note stentgraft (curved arrow). b Weighted average DECT image at the same slice position. The endoleak (arrow) is less conspicuous, measuring 220 HU. c Virtual NC DECT image at the same slice position. Note iodine has been subtracted, confirming the endoleak (arrow). Note calcified thrombus in the aneurysm sac (curved arrow)...

---